Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.43 |
| ▸ | ANPEP | P15144 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | ALPI | P09923 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | XIAP | P98170 | 1/20 | 0.41 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30657566 | 0.78 | EPHX1 (0.55) | EPHX1TAAR1SLC6A2SIGMAR1MAOA | |
| SCHEMBL184702 | 0.78 | EPHX1 (0.55) | EPHX1TAAR1SLC6A2SIGMAR1MAOA | |
| SCHEMBL252017 | 0.78 | EPHX1 (0.55) | EPHX1TAAR1SLC6A2SIGMAR1MAOA | |
| SCHEMBL1278885 | 0.74 | EPHX1 (0.50) | EPHX1TAAR1SLC6A2SIGMAR1MAOA | |
| SCHEMBL219294 | 0.74 | EPHX1 (0.50) | EPHX1TAAR1SLC6A2SIGMAR1MAOA | |
| SCHEMBL564024 | 0.74 | EPHX1 (0.50) | EPHX1TAAR1SLC6A2SIGMAR1MAOA | |
| SCHEMBL5146904 | 0.74 | EPHX1 (0.50) | EPHX1TAAR1SLC6A2SIGMAR1MAOA | |
| SCHEMBL707068 | 0.74 | EPHX1 (0.50) | EPHX1TAAR1SLC6A2SIGMAR1MAOA | |
| SCHEMBL5609928 | 0.74 | EPHX1 (0.50) | EPHX1TAAR1SLC6A2SIGMAR1MAOA | |
| SCHEMBL66064 | 0.74 | SIGMAR1 (0.58) | EPHX1TAAR1SLC6A2SIGMAR1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6852723-B2 | Aralkyl substituted piperazine compounds | CV THERAPEUTICS, INC. (US) | 2005-02-08 | — | — | US | disclosed |
| EP-1463697-A2 | SYNTHESIS OF ALFA,BETA,BETA-TRIFLUOROSTYRENE VIA IN-SITU FORMATION OF TRIFLUOROVINYL METAL HALIDE | BALLARD POWER SYSTEMS INC. (CA) | 2004-10-06 | — | — | EP | disclosed |
| US-6737434-B2 | HAVING ACTIVITIES ANALOGOUS TO THOSE EXHIBITED BY GRANULOCYTE-COLONY STIMULATING FACTOR; FOR THERAPY OF IMMUNE DISEASES WHICH ACCOMPANY REDUCTION IN NEUTROPHILS CAUSED BY CHEMOTHERAPY OR RADIOTHERAPY OF CANCER | SSP CO., LTD. (JP) | 2004-05-18 | — | — | US | disclosed |
| US-6653515-B2 | One pot process comprising reacting tetrafluoroethylene with bases, metal halides and optionally amines to form trifluorovinyl metal complexes, then arylating in the presence of catalysts to form trifluorophenylethylene | BALLARD POWER SYSTEMS INC. (CA) | 2003-11-25 | — | — | US | disclosed |
| US-20030176482-A1 | Imidazole derivatives or their salts | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 2003-09-18 | — | — | US | disclosed |
| US-20030176440-A1 | Aralkyl substituted piperazine compounds | CV THERAPEUTICS, INC. | 2003-09-18 | — | — | US | disclosed |
| US-20030144439-A1 | Synthesis of alpha, beta, beta-trifluorostyrene via in-situ formation of trifluorovinyl metal halide | BALLARD POWER SYSTEMS INC. (CA) | 2003-07-31 | — | — | US | disclosed |
| WO-2003051801-A2 | SYNTHESIS OF ALPHA, BETA, BETA-TRIFLUOROSTYRENE VIA IN-SITU FORMATION OF TRIFLUOROVINYL METAL HALIDE | BALLARD POWER SYSTEMS INC. (CA) | 2003-06-26 | — | — | WO | disclosed |
| EP-1319658-A1 | IMIDAZOLE DERIVATIVES OR THEIR SALTS | SSP Co., Ltd. (JP) | 2003-06-18 | — | — | EP | disclosed |
| US-6552023-B2 | N-(2,6-dimethylphenyl)-2-(4-(2-hydroxy-4-phenylbutyl) -piperazinyl)acetamide, for example; useful to protect skeletal muscles against damage from trauma or disease, treat shock, preserve donor tissue or organs; greater half-life | CV THERAPEUTICS, INC. | 2003-04-22 | — | — | US | disclosed |
| EP-1259493-A2 | SUBSTITUTED PIPERAZINE COMPOUNDS | CV THERAPEUTICS, INC. (US) | 2002-11-27 | — | — | EP | disclosed |
| US-20010041704-A1 | N-(2,6-dimethylphenyl)-2-(4-(2-hydroxy-4-phenylbutyl) -piperazinyl)acetamide, for example; useful to protect skeletal muscles against damage from trauma or disease, treat shock, preserve donor tissue or organs; greater half-life | CV THERAPEUTICS, INC. | 2001-11-15 | — | — | US | disclosed |
| WO-2001062744-A2 | SUBSTITUTED PIPERAZINE COMPOUNDS | CV THERAPEUTICS, INC. (US) | 2001-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010041704-A1 | N-(2,6-dimethylphenyl)-2-(4-(2-hydroxy-4-phenylbutyl) -piperazinyl)acetamide, for example; useful to protect skeletal muscles against damage from trauma or disease, treat shock, preserve donor tissue or organs; greater half-life | TNNC1, ATP2A1, ATP2A2 | EPHX1 2631/4885TAAR1 4462/4885SLC6A2 1864/4885 |
| US-20030176482-A1 | Imidazole derivatives or their salts | CSF3R, CSF1R, FLT3 | EPHX1 3831/4885TAAR1 1392/4885SLC6A2 4476/4885 |
| US-20030144439-A1 | Synthesis of alpha, beta, beta-trifluorostyrene via in-situ formation of trifluorovinyl metal halide | SLC6A12, SLC30A7, SLC39A11 | EPHX1 3459/4885TAAR1 239/4885SLC6A2 968/4885 |
| US-20030176440-A1 | Aralkyl substituted piperazine compounds | ATP2A1, ATP2A3, ATP2A2 | EPHX1 1970/4885TAAR1 4289/4885SLC6A2 4208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.